Article Information
History
- October 13, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- John R. Ellis1,*,
- Nyamai Mutono2,3,
- Andreia Vasconcelos4,5,
- SM Thumbi2,3,6,
- T. Déirdre Hollingsworth4 and
- Roy M. Anderson1
- 1Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, White City Campus, Imperial College London, London, United Kingdom
- 2Centre for Epidemiological Modelling and Analysis, University of Nairobi, Kenya
- 3Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, USA
- 4Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, United Kingdom
- 5Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, United Kingdom
- 6Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, UK
- ↵*Corresponding author E-mail: john.ellis{at}imperial.ac.uk
Posted October 13, 2024.
How improvements to drug effectiveness impact mass drug administration for control and elimination of schistosomiasis
